Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 1,801–1,900 of 2,576
Hashimoto, T., Ogino, K., Shin, R., Kitamoto, T., Kikuchi, T., & Shimizu, N. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.12.015 · Cited by 13
Lessard, C. B., Cottrell, B. A., Maruyama, H., Suresh, S., Golde, T. E., & Koo, E. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144758 · Cited by 14
Transcriptional regulation of the presenilin-1 gene controls gamma-secretase activity
Das, H. K. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e61 · Cited by 14
“Various PS1 mutations and PS1 deficiency are known to alter the PS1/gamma-secretase activity and thus the production of Abeta peptides (25-32).”
BackgroundMethodAnticoagulants inhibit proteolytic clearance of plasma amyloid beta
Yang, L., Bhattacharya, A., Li, Y., & Zhang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23718 · Cited by 12
Mitri, E., Barbieri, L., Vaccari, L., & Luchinat, E. (2018) · The Analyst · doi:10.1039/c7an01464c · Cited by 14
Ohshima, Y., Taguchi, K., Mizuta, I., Tanaka, M., Tomiyama, T., Kametani, F., Yabe‐Nishimura, C., Mizuno, T., & Tokuda, T. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00511 · Cited by 12
Translational medicine of the glutamate AMPA receptor
Miyazaki, T., Hiroki, A. B. E., Uchida, H., & Takahashi, T. (2021) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.97.001 · Cited by 13
γ-Secretase inhibitors: still in the running as Alzheimer’s therapeutics
Marjaux, E., & Strooper, B. D. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.05.001 · Cited by 13
Zhang, S. X., Guo, Y., & Boulianne, G. L. (2001) · Gene · doi:10.1016/s0378-1119(01)00770-3 · Cited by 14
Villemagne, V. L., Ng, S., Cappai, R., Barnham, K. J., Fodero‐Tavoletti, M. T., Rowe, C. C., & Masters, C. L. (2006) · The Neuroradiology Journal · doi:10.1177/197140090601900406 · Cited by 12
Molecular aspects of neurodegeneration in Alzheimer's disease.
Russo, C., Venezia, V., Salis, S., Dolcini, V., & Schettini, G. (2002) · PubMed · Cited by 15
Monster plaques: What they tell us about Alzheimer's disease
Yankner, B. A. (1998) · Nature Medicine · doi:10.1038/nm0498-394 · Cited by 12
Bhagavan, S., Ibarreta, D., Ma, D., Kozikowski, A. P., & Etcheberrigaray, R. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0195 · Cited by 16
“…the identification of a number of cellular/molecular alterations that may be the reflection of comparable processes in the AD brain and thus, of pathophysiological relevance (Baker et al., 1988; Scott, 1993; Huang, 1994; Scheuner et al., 1996; Etcheberrigaray & Alkon, 1997; Gasparini et al., 1997).”
BackgroundShanahan, C., Gibson, G. E., Cowburn, R. F., Johnston, J. A., Wiehager, B., Lannfelt, L., & O’Neill, C. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00572-7 · Cited by 12
Self-citationClinical rationale of genetic testing in dementia.
Frisoni, G. B., & Trabucchi, M. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.3.217 · Cited by 13
Hedera, P., & Turner, R. S. (2002) · Neurologic Clinics · doi:10.1016/s0733-8619(01)00020-2 · Cited by 12
Cortical neurodegeneration caused by Psen1 mutations is independent of Aβ
Yan, K., Zhang, C., Kang, J., Montenegro, P., & Shen, J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409343121 · Cited by 13
The p3 peptides (Aβ17-40/42) rapidly form amyloid fibrils that cross-seed with full-length Aβ
Tian, Y., Torres‐Flores, A. P., Shang, Q., Zhang, H., Khursheed, A., Tahirbegi, I. B., Pallier, P. N., & Viles, J. H. (2025) · Nature Communications · doi:10.1038/s41467-025-57341-4 · Cited by 13
Unraveling the mystery of citrate transporters in Alzheimer’s disease: An updated review
Mukherjee, A. G., Mishra, S., Gopalakrishnan, A. V., Kannampuzha, S., Murali, R., Wanjari, U. R., Stany, B. K., Vellingiri, B., Madhyastha, H., Deepankumar, K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102726 · Cited by 12
Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype
Parker, J. B., Mozaffar, T., Messmore, A., Deignan, J. L., Kimonis, V. E., & Ringman, J. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.01.047 · Cited by 11
Human-Derived Brain Models: Windows into Neuropsychiatric Disorders and Drug Therapies
Papariello, A. R., & Litwa, K. (2019) · Assay and Drug Development Technologies · doi:10.1089/adt.2019.922 · Cited by 15
Chiasseu, M., Fesharaki‐Zadeh, A., Saito, T., Saido, T. C., & Strittmatter, S. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105059 · Cited by 11
“Mutations in the APP gene (Scheuner et al., 1996; Selkoe and Hardy, 2016) and repeated concussive injuries (Montenigro et al., 2017; Nolan et al., 2018), detrimentally affect cognition.”
BackgroundKang, H. S., Kim, J. H., Lim, H. S., Kim, J., Noh, H., Choi, H. G., Min, K., Kim, N. Y., & Kwon, M. J. (2023) · Cancers · doi:10.3390/cancers15184615 · Cited by 13
“AD is linked to extensive neuritic and synaptic degeneration and neuronal cell death, either induced by or concurrently with the deposition of abnormal β-amyloid and tau [7,8].”
BackgroundMendonsa, G. R., Zakaria, J. A. D., Lin, A., Vijairania, P., Jong, Y.-J. I., & Baenziger, N. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004655 · Cited by 16
“This compares with PS-1 A246E and L286V mutations whose age of AD onset is generally later than 40 and whose fibroblasts secrete 2-3-fold more Ab1–42 than normals [53,54].”
BackgroundKwon, H.-C., Cha, J. W., Park, J., Chun, Y.-S., Moodley, N., Maharaj, V. J., Youn, S.-H., Chung, S., & Yang, H.-O. (2011) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2011.19.1.090 · Cited by 11
“Aβ is produced by sequential proteolytic cleavages of the βamyloid precursor protein (APP) by a set of membrane-bound proteases termed β-secretase and γ-secretase (Iwatsubo et al., 1994; Scheuner et al., 1996).”
BackgroundDutta, M., & Mattaparthi, V. S. K. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1296783 · Cited by 11
“Studies have also shown that overproduction of Aβ42 relative to Aβ40 have been related to some early onset versions of AD (Scheuner et al., 1996).”
BackgroundDepletion of amyloid‐β peptides from solution by sequestration within fibril‐seeded hydrogels
Yau, W., & Tycko, R. (2018) · Protein Science · doi:10.1002/pro.3387 · Cited by 11
Retinal Changes in Transgenic Mouse Models of Alzheimer’s Disease
Guo, L., Ravindran, N., Shamsher, E., Hill, D., & Cordeiro, M. F. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210414113634 · Cited by 14
Soto-Ospina, A., Marín, P. A., Bedoya, G., & Lanau, A. V. (2021) · Biochemistry Research International · doi:10.1155/2021/9542038 · Cited by 15
Human Herpesvirus 6A U4 Inhibits Proteasomal Degradation of the Amyloid Precursor Protein
Tang, T., Jia, J., Garbarino, E., Chen, L., Ma, J., Li, P., Chen, X., Wang, L., Wen, Y., Wang, Y., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01688-21 · Cited by 12
Kumari, A., Rahaman, A., Zeng, X., Farooq, M. A., Huang, Y., Yao, R., Ali, M., Ishrat, R., & Ali, R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.966877 · Cited by 12
Expression of Presenilin 1 mRNA in Rat Peripheral Organs and Brain
Nilsberth, C., Luthman, J., Lannfelt, L., & Schultzberg, M. (1999) · The Histochemical Journal · doi:10.1023/a:1003887922777 · Cited by 11
Self-citationTodd, S., McKnight, A. J., Liu, W. W., Carson, R., Heggarty, S., McGuinness, B., Irvine, G. B., Craig, D., Passmore, A. P., & Johnston, J. A. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8045-y · Cited by 12
“Although APP and presenilin mutations have different primary molecular effects, these converge to increase the production of Ab (total), or selectively increase the production of 42 amino acid Ab (Johnston et al. 1994; Scheuner et al. 1996).”
BackgroundPresenilin‐I polymorphism and hereditary cerebral hemorrhage with amyloidosis, Dutch type
Bornebroek, M., Haan, J., Backhovens, H., Deutz-Terlouw, P. P., van Buchem, M. A., den Broeck, M. V., Bakker, E., Roos, R. A. C., & Broeckhoven, C. V. (1997) · Annals of Neurology · doi:10.1002/ana.410420116 · Cited by 11
Fujiwara, Y., Takahashi, M., Tanaka, M., Hoshi, T., Someya, T., & Shinkai, S. (2003) · Gerontology · doi:10.1159/000073765 · Cited by 12
Janssen, L., Keppens, C., Deyn, P. P. D., & Dam, D. V. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.027 · Cited by 18
BACE1 Gene Expression and Protein Degradation
Zhou, W., Qing, H., Tong, Y., & Song, W. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.004 · Cited by 15
Modulation of neutrophil apoptosis by β-amyloid proteins
Park, H., Park, J., Baek, D.-W., Lee, S., Lee, M.-J., Jin, J., Kim, J., Hong, Y., Lee, Y.-H., & Kwak, J. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.01.019 · Cited by 11
Molecular pathology of Alzheimer's disease
Yamazaki, T., & Ihara, Y. (1997) · Neuropathology · doi:10.1111/j.1440-1789.1997.tb00051.x · Cited by 11
Li, Q., Cappai, R., Evin, G. M., Tanner, J. E., Gray, C. W., Beyreuther, K. T., & Masters, C. L. (1998) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331759801300504 · Cited by 11
“As shown in Figure IB, Ab(1-25) precipitated a band of -l26 kDa which reacted with mAb W02 but not with mAb lA9, consistent with the specificity of mAb lA9.”
BackgroundMethodInfluentialTau protein as a therapeutic target in Alzheimer’s disease and other neurodegenerative disorders
Larner, A. J. (1999) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.9.10.1359 · Cited by 11
Is γ-secretase a multienzyme complex for membrane protein degradation?
Small, D. H. (2002) · Peptides · doi:10.1016/s0196-9781(02)00072-4 · Cited by 11
Anthelmintic efficacy of flubendazole paste against nematodes and cestodes in dogs and cats
Vanparijs, O., Hermans, L., & der Flaes, L. V. (1985) · American Journal of Veterinary Research · doi:10.2460/ajvr.1985.46.12.2539 · Cited by 13
Tomidokoro, Y., Ishiguro, K., Igeta, Y., Matsubara, E., Kanai, M., Shizuka, M., Kawarabayashi, T., Harigaya, Y., Kawakatsu, S., Ii, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.0119 · Cited by 11
Willumsen, N., Arber, C., Lovejoy, C. E. J., Toombs, J., Alatza, A., Weston, P. S. J., Chávez‐Gutiérrez, L., Hardy, J., Zetterberg, H., Fox, N. C., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac321 · Cited by 10
Self-citationMechanisms of Microglial Activation by Amyloid Precursor Protein and its Proteolytic Fragments
Austin, S. A., & Combs, C. K. (2007) · Springer eBooks · doi:10.1007/978-0-387-73894-9_2 · Cited by 11
“The best characterized consequence of these mutations is an alteration in proteolytic processing of APP leading to elevated secretion of the longer Aβ peptide, amino acids 1–42 (Citron et al., 1992, 1994; Scheuner et al., 1996; Suzuki et al., 1994;).”
BackgroundScreening of Crucial Differentially-Methylated/Expressed Genes for Alzheimer’s Disease
Qiu, H., & Weng, Q. (2022) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175221116220 · Cited by 15
“AD may occur either sporadically or on a hereditary basis, which are related to certain genetic mutations.(5,6) Diagnosis approaches to AD have been improved clearly over the last hundred years, which contains neuropsychological tests, cerebrospinal fluid (CSF) or plasma analyses, and image analysis.”
BackgroundThe amyloid-β peptide: Guilty as charged?
Murphy, M. P., Buzinova, V. A., & Johnson, C. E. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166945 · Cited by 14
Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer’s disease
Iaccarino, L., Llibre‐Guerra, J. J., McDade, E., Edwards, L., Gordon, B. A., Benzinger, T. L. S., Hassenstab, J. J., Kramer, J. H., Li, Y., Miller, B. L., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae159 · Cited by 11
Role of PIM Kinase Inhibitor in the Treatment of Alzheimer’s Disease
Meur, S., Mukherjee, S., Roy, S., & Karati, D. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04257-7 · Cited by 10
“Mutations in PS-1 and PS-2, the primary components of the secretase complex that cause familial AD, also accelerate the processing of APP to produce amyloidogenic Aβ [38].”
Cell Signaling Abnormalities May Drive Neurodegeneration in Familial Alzheimer Disease
Robakis, N. K. R. K. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1003-6 · Cited by 12
Rossor, M. N. (1999) · Journal of Neurology · doi:10.1007/s004150050298 · Cited by 10
Disease‐modifying therapy for Alzheimer's disease: Challenges and hopes
Iwata, A., & Iwatsubo, T. (2013) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.20 · Cited by 10
The Potential Role of Epigenetics in Alzheimer?s Disease Etiology
Shewale, S., & Huebinger, R. M. (2012) · Biological Systems Open Access · doi:10.4172/2329-6577.1000114 · Cited by 13
Katzov, H., Bennet, A. M., Höglund, K., Wiman, B., Lütjohann, D., Brookes, A. J., Andreasen, N., Blennow, K., Fairé, U. D., & Prince, J. A. (2005) · Journal of Human Genetics · doi:10.1007/s10038-005-0341-x · Cited by 11
“In addition, other genes proven to influence AD (APP, PSEN1, and PSEN2) (Goate et al. 1991; Rogaev et al. 1995; Sherrington et al. 1995) have been shown to be involved in Ab metabolism (Scheuner et al. 1996).”
Hardy, J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01304 · Cited by 11
“…or by mutations which make protein deposition more likely either by changing the cleavage profile of Aβ so that a less soluble form is released (Scheuner et al., 1996) or by altering the splicing pattern of the MAPT gene so that more of the four repeat isoform of tau is produced (Hutton et…”
BackgroundSelf-citationIdentification of amyloid beta mid-domain fragments in human cerebrospinal fluid
Røgeberg, M., Wettergreen, M., Nilsson, L. N. G., & Fladby, T. (2015) · Biochimie · doi:10.1016/j.biochi.2015.03.022 · Cited by 11
Diagnostic biologique de la maladie d’Alzheimer : avancées, limites et perspectives
Malaplate, C., Desbène, C., Pillot, T., & Olivier, J. L. (2008) · Revue Neurologique · doi:10.1016/j.neurol.2008.10.015 · Cited by 17
“Actuellement, seules les formes familiales de MA associées à des mutations des gènes des présénilines ou de l’APP et la trisomie 21 sont clairement associées à l’augmentation du taux plasmatique d’Ab (Scheuner et al., 1996 ; Kosaka et al., 1997 ; Schupf et al., 2001).”
BackgroundEffects of Colostrinin™ on gene expression-transcriptomal network analysis
Szaniszlo, P., Germán, P., Hajas, G., Saenz, D. N., Woodberry, M. W., Kruzel, M. L., & Boldogh, I. R. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2008.10.022 · Cited by 12
Alzheimer's disease and HIV associated dementia related genes: I. location and function
Shapshak, P., Rodriguez, H. E., Kayathri, R., Levine, A. J., Chiappelli, F., & Minagar, A. (2008) · Bioinformation · doi:10.6026/97320630002348 · Cited by 12
Pan, Y., Jia, X.-T., Wang, X., Chen, X., Li, Q., Gao, X., & Qi, J. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.03.003 · Cited by 10
Secretases as targets for beta‐amyloid lowering drugs
Walter, J., & Haass, C. (2002) · Drug Development Research · doi:10.1002/ddr.10076 · Cited by 11
“…an involvement of PS proteins in g-secretase activity came from the observation that all FAD associated mutations in PSs analysed in cultured cells elevate the generation of Ab42 [Younkin, 1998], which is consistent with Ab measurements in blood plasma of mutation carriers [Scheuner et al., 1996].”
Recent Advances from the Bench Toward the Bedside in Alzheimer's Disease
Macauley, S. L., & Holtzman, D. M. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.01.002 · Cited by 10
“Approximately 20 years ago (Scheuner et al., 1996), several mutations in the genes encoding amyloid precursor protein (APP) and presenilin (PSEN) were discovered to give rise to early-onset familial AD (FAD) through the increased production of the plaque forming peptide, Aβ.”
BackgroundKincses, Z. T., Király, A., Veréb, D., & Vécsei, L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143195 · Cited by 12
Hwang, D. Y., Cho, J. S., Kim, C. K., Shim, S. B., Jee, S. W., Lee, S. H., Seo, S. J., Cho, J. Y., Lee, S. H., & Kim, Y. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-7952-7 · Cited by 10
Kindy, M. S., Yu, J., Zhu, H., Bhat, A. N., El-Sayed, H., Gattoni‐Celli, S., & Gudz, T. I. (2015) · Neuroimmunology and Neuroinflammation · doi:10.4103/2347-8659.149421 · Cited by 10
“[6-10] Early onset autosomal dominant AD is directly”
BackgroundChlamydia pneumoniae, APOE genotype, and Alzheimer’s disease
Hudson, A. P., Gérard, H. C., Whittum‐Hudson, J. A., Appelt, D. M., & Balin, B. J. (2000) · Springer eBooks · doi:10.1007/978-3-642-57195-4_19 · Cited by 10
Cell cycle and chromosome segregation defects in alzheimer's disease
Potter, H., Geller, L. N., Thomas, A. E., Conforto, D., & Chichkova, R. I. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)83340-0 · Cited by 10
Tolédano, A., Alvarez, M. I., Rivas, L., Lacruz, C. R., & Martínez-Rodríguez, R. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050231 · Cited by 11
“APP overexpression similar to that in patients with DS who develop AD has not been clearly demonstrated in sporadic AD (Scheuner et al., 1996).”
BackgroundTanimukai, H., Sato, K., Kudo, T., Kashiwagi, Y., Tohyama, M., & Takeda, M. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00438-2 · Cited by 10
Oxidative Stress in Alzheimer’s Disease
Ceballos-Picot, I. (1997) · Neuroscience intelligence unit · doi:10.1007/978-3-662-22516-5_5 · Cited by 10
What do we learn from a few familial Alzheimer’s disease cases?
Haass, C., & Baumeister, R. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-7508-8_13 · Cited by 11
van Dijk, R., Fischer, D. F., Sluijs, J. A., Sonnemans, M. A. F., Hobo, B., Mercken, L., Mann, D. M. A., Hol, E. M., & van Leeuwen, F. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02528.x · Cited by 12
“Mutations in the genes for presenilin 1 and 2 modulate c-secretase cleavage of APP, also leading to an increase in the production of this more amyloidogenic form of Ab (Borchelt et al. 1996; Scheuner et al. 1996).”
BackgroundUtsumi, K. (1998) · Acta Oto-Laryngologica · doi:10.1080/00016489850154702 · Cited by 10
Presenilin 1 Cleavage is a Universal Event in Human Organs
Okochi, M., Sahara, N., Kametani, F., Usami, M., Arai, T., Tanaka, K., Ishii, K., Yamamoto, A., & Mori, H. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00045-1 · Cited by 12
Inhibition of insulin-degrading enzyme in human neurons promotes amyloid-β deposition
Rowland, H. A., Moxon, S. R., Corbett, N. J., Hanson, K., Fisher, K., Kellett, K. A. B., & Hooper, N. M. (2023) · Neuronal Signaling · doi:10.1042/ns20230016 · Cited by 190
Najdaghi, S., Davani, D. N., Fouladseresht, H., Ebrahimi, N., Sullman, M. J. M., Moradi, M., & Eskandari, N. (2024) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-024-01518-w · Cited by 12
Trambauer, J., Sarmiento, R. M. R., Garringer, H. J., Salbaum, K. A., Pedro, L. D., Crusius, D., Vidal, R., Ghetti, B. F., Paquet, D., Baumann, K., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01680-3 · Cited by 9
“The aberrantly increased ratios of Aβ42 or Aβ43, respectively, to Aβ40 are considered to be decisive determinants for the pathogenesis of FAD [10], and can be used for correlations with FAD age of onset.”
Some Remarks on Biological Markers of Alzheimer’s Disease
Robles, A. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00011-6 · Cited by 9
Li, N., Qiu, Y., Wang, H., Zhao, J., & Qing, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416151 · Cited by 9
Nath, S., Buell, A. K., & Barz, B. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp05961d · Cited by 9
Wu, M., Li, Y., Miao, Y., Qiao, H., & Wang, Y. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2245582 · Cited by 12
Feng, B., Hu, P., Chen, J., Liu, Q., Li, X., & Du, Y. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514537548 · Cited by 11
Tagami, S., Okochi, M., Yanagida, K., Kodama, T. S., Arai, T., Kuwano, R., Ikeuchi, T., & Takeda, M. (2013) · Neurodegenerative Diseases · doi:10.1159/000355258 · Cited by 9
Abnormal cross‐talk between mutant presenilin 1 ( I143T, G384A ) and glycosphingolipid biosynthesis
Mutoh, T., Kawamura, N., Hirabayashi, Y., Shima, S., Miyashita, T., Ito, S., Asakura, K., Araki, W., Cazzaniga, E., Muto, E., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-198630 · Cited by 11
Patient-derived iPSCs, a reliable in vitro model for the investigation of Alzheimer’s disease
Asiamah, E. A., Guo, R., Kong, D., Feng, B., He, J., Zhang, W., Liu, X., Du, X., Ma, Z., Liu, B., et al. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0065 · Cited by 10
Balasa, M., Dídac Vidal-piñeiro, A., Lladó, A., Antonell, A., Bosch, B., Castellanos, F., Bargalló, N., Bartrés‐Faz, D., Molinuevo, J. L., & Sánchez‐Valle, R. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111949 · Cited by 12
“The different PSEN1 mutations affect -secretase function in different ways to produce a lifetime increase of the A 42/A 40 ratio [31, 32].”
BackgroundRingman, J. M., Tomic, J. L., Coppola, G., Elashoff, D. A., Gylys, K. H., & Glabe, C. G. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000345771 · Cited by 9
Platelet α- and β-secretase activities: A preliminary study in normal human subjects
Smith, C., Prichard, B. N. C., & Cooper, M. B. (2009) · Platelets · doi:10.1080/09537100802334434 · Cited by 9
Chun, Y. S., Oh, H. G., Park, M. K., Kim, T., & Chung, S. (2013) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/407903 · Cited by 9
“Hindawi Publishing Corporation Journal of Neurodegenerative Diseases Volume 2013, Article ID 407903, 12 pages http://dx.doi.org/10.1155/2013/407903”
BackgroundInfluentialGenética de las enfermedades neurodegenerativas más prevalentes
Lladó, A., Gaig, C., & Molinuevo, J. L. (2006) · Medicina Clínica · doi:10.1157/13087844 · Cited by 11
Attar, A., Meral, D., Urbanc, B., & Bitan, G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394431-3.00038-9 · Cited by 13
“Clinically, Aβ42 has been most closely associated with AD because: (1) FAD-linked mutations in the psen1 and psen2 genes, which encode the catalytic unit of γ-secretase, presenilin-1 and presenilin-2, respectively, result in increased Aβ42 levels [12,13]; and (2) Aβ42 is more prone to aggregation [3,14,15] and is more…”
Background3,4-Methylenedioxymethamphetamine (MDMA), but not morphine, alters APP processing in the rat brain
Kalman, J. L., Bjelik, A., Hugyecz, M., Tímár, J., Gyarmati, Z., Zana, M., Fürst, Z., Janka, Z., Rakonczay, Z., Horváth, Z., et al. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570600650x · Cited by 11
“…forms of AD, a subtle balance exists between the normal, a-secretasemediated cleavage of APP, resulting in soluble, secreted and neuroprotective aAPPs, and the abnormal , b-and c-secretase-mediated proteolysis, which leads to neurotoxic bAP production and deposition (Scheuner et al., 1996).”
BackgroundSwitched Aβ43 generation in familial Alzheimer’s disease with presenilin 1 mutation
Kakuda, N., Takami, M., Okochi, M., Kasuga, K., Ihara, Y., & Ikeuchi, T. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01684-1 · Cited by 10
Quan, W., Yasuda, M., Hashimoto, M., Yamamoto, Y., Ishii, K., Kazui, H., Mori, E., Kakigi, T., & Maeda, K. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.09.004 · Cited by 9
Biomarker identification in neurologic diseases: improving diagnostics and therapeutics
Coon, K. D., Dunckley, T. L., & Stephan, D. A. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.3.361 · Cited by 9
Yeast prions, mammalian amyloidoses, and the problem of proteomic networks
Galkin, A. P., Mironova, L. N., Zhouravleva, G. A., & Inge-Vechtomov, S. G. (2006) · Russian Journal of Genetics · doi:10.1134/s1022795406110135 · Cited by 9
“There is evidence that γ-secretase is a complex of several proteins, including presenilins 1 and 2 (PS1 and PS2) [73].”
BackgroundCui, P., Cao, L. H., Wang, Y., Deng, Y., Xu, W. L., Wang, G., Zhang, Y., Zheng, L., Fei, Q.-Z., Zhang, T., et al. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2011.08.036 · Cited by 9
Alzheimer’s Disease and Dementia
Lewis, P. A., & Spillane, J. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811069-0.00002-1 · Cited by 11
Zhao, L., Cheng, X., & Zhong, C. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00450 · Cited by 9
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.